CTLA4 and melanoma: Ipilimumab, an anti-CTLA-4 monoclonal antibody, leading to depletion of regulatory T cells, resulted in clinical efficacy in melanoma patients in an Fc-mediated manner, which may be partly due to relieved NK cell cytotoxicity suppressed by Tregs (320, 321).